Companies · Biotechnology

Benten BioServices, Inc.

MALVERN · Biotechnology

Diligence memoA one-page analyst read on Benten BioServices, Inc. — recommendation, valuation, rhythm, risks.
$9.4M
Total raised · real
5
Rounds
0.8×
Latest step-up
Top 46%
Sector rank · raised
Seed
Latest stage · inferred · Thu Sep 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Benten BioServices, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.67× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era.
  • Within the normal band (67% of peer median) for its niche.
Dormant
  • Last raise 13.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Benten BioServices, Inc. is one of 4291 Biotechnology companies tracked from MALVERN. By capital raised it ranks mid-pack (ahead of 55% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2011-12-21 Raised $2.7M (real) Modeled valuation $122M (est)$2.7M$122MSeed2011Seed · 2011-12-21 Raised $1.3M (real) Modeled valuation $57M (est)$1.3M$57MSeed2011Seed · 2012-08-14 Raised $2.9M (real) Modeled valuation $131M (est)$2.9M$131MSeed2012Seed · 2012-09-20 Raised $1.3M (real) Modeled valuation $58M (est)$1.3M$58MSeed2012Seed · 2012-09-20 Raised $1.1M (real) Modeled valuation $49M (est)$1.1M$49MSeed2012+$1.3M+$2.9M+$1.3M+$1.1MCumulative $9.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.7M · 2011
Seed extension$1.3M · 2011
Seed extension$2.9M · 2012
Seed extension$1.3M · 2012
Seed extension$1.1M · 2012

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$58.4M
Base estimate est.
$947K
Conservative case
$458.1M
Upside case
$6.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $121.6M · 2011-12-212011Seed · modeled $56.6M · 2011-12-21Seed · modeled $130.7M · 2012-08-14Seed · modeled $58.4M · 2012-09-20Seed · modeled $48.8M · 2012-09-202012
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
13.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
2 mo
Avg between rounds
$12.5M/yr
Capital velocity
14.5 yr
On record since
2011
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.3× above median
This company$9.4M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.6× of median
This company$1.1M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.9× of median
This company$58.4M
Sector median$64.2M

Raised more than 55% of sector peers (real $). Modeled value above 49% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #107 of 151.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Signum Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Denali Medical II, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Health Elements, LLC · Seed Raised $4.0M · modeled $177.6M (est)Nkt Therapeutics Inc · Seed Raised $4.0M · modeled $177.6M (est)Surface Logix Inc · Seed Raised $4.0M · modeled $177.6M (est)Fe3 Medical, Inc. · Seed Raised $5.4M · modeled $177.1M (est)Proteonomix, Inc. · Seed Raised $3.8M · modeled $169.0M (est)SRS Medical Systems, Inc. · Seed Raised $3.8M · modeled $167.4M (est)Origen Therapeutics Inc /Ca · Seed Raised $3.7M · modeled $166.2M (est)Vivebio, LLC · Seed Raised $3.7M · modeled $163.1M (est)O2 Medtech Inc · Seed Raised $7.1M · modeled $160.3M (est)Biothera, Inc. · Seed Raised $3.5M · modeled $155.4M (est)Benten BioServices, Inc. (this company) Raised $9.4M · modeled $58.4M (est)Benten BioServices, Inc.
CompanyStageRaised · realValue · estvs peer med.
Signum Biosciences, Inc.Seed$4.0M$177.6M2.05×
Denali Medical II, Inc.Seed$4.0M$177.6M2.05×
Health Elements, LLCSeed$4.0M$177.6M2.05×
Nkt Therapeutics IncSeed$4.0M$177.6M2.05×
Surface Logix IncSeed$4.0M$177.6M2.05×
Fe3 Medical, Inc.Seed$5.4M$177.1M2.05×
Proteonomix, Inc.Seed$3.8M$169.0M1.95×
SRS Medical Systems, Inc.Seed$3.8M$167.4M1.93×
Origen Therapeutics Inc /CaSeed$3.7M$166.2M1.92×
Vivebio, LLCSeed$3.7M$163.1M1.88×
O2 Medtech IncSeed$7.1M$160.3M1.85×
Biothera, Inc.Seed$3.5M$155.4M1.79×
Benten BioServices, Inc. this companySeed$9.4M$58.4M0.67×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.7M2011-12-21$13.7M$121.6M90%
Seed$1.3M2011-12-21$6.4M$56.6M90%
Seed$2.9M2012-08-14$14.7M$130.7M90%
Seed$1.3M2012-09-20$6.6M$58.4M90%
Seed$1.1M2012-09-20$5.5M$48.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.7M2011-12-21
    • First recorded raise — entered as Seed.
  2. Seed$1.3M2011-12-21
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× smaller than the prior — bridge or down round.
  3. Seed$2.9M2012-08-14
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
  4. Seed$1.3M2012-09-20
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 2.2× smaller than the prior — bridge or down round.
  5. Seed$1.1M2012-09-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
Intelligence
2012 ~Q4
Modeled next raise · ~2mo cadence
$1.1M
Modeled next size est.range $1.1M$1.8M
0.8×
Last step-up
$12.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Bernard Chaunce Rudnick2012-09
David Chaunce McLachlan2011-12
Kevin Chaunce Harter2011-12
Michele Chaunce Washko2011-12
Paula Z MacDonald2011-12
Thomas Chaunce Penn2011-12
Warren Chaunce Bogard2011-12
Registry & provenance

Benten BioServices, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1538610
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Sun BioPharma, Inc.BiotechnologySeed$8.0M$52.2Msame sector · same stage
PhysioSonics, IncBiotechnologySeed$7.9M$66.6Msame sector · same stage
Bacterin International, Inc.BiotechnologySeed$11.3M$48.2Msame sector · same stage
Launchcyte LlcBiotechnologySeed$7.8M$46.8Msame sector · same stage
Linkage Biosciences, Inc.BiotechnologySeed$7.4M$68.6Msame sector · same stage
Protalex IncBiotechnologySeed$7.3M$63.3Msame sector · same stage
Hancock Jaffe Laboratories, Inc.BiotechnologySeed$6.8M$67.0Msame sector · same stage
Prometheon Pharma, LlcBiotechnologySeed$6.7M$50.3Msame sector · same stage
Frequently asked
How much funding has Benten BioServices, Inc. raised?
Benten BioServices, Inc. has raised approximately $9.4M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Benten BioServices, Inc.'s estimated valuation?
Provath's modeled valuation for Benten BioServices, Inc. is approximately $58.4M (modeled range $947K–$458.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Benten BioServices, Inc. at?
Benten BioServices, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Thu Sep 20.
What does Benten BioServices, Inc. do and where is it based?
Benten BioServices, Inc. operates in the Biotechnology sector, based in MALVERN.
Explore related

See where Benten BioServices, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Benten BioServices, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.